Literature DB >> 34670824

Non-invasive markers for sudden cardiac death risk stratification in dilated cardiomyopathy.

Vivetha Pooranachandran1,2, Will Nicolson1,3, Zakariyya Vali1,3, Xin Li1,4, G Andre Ng5,2,3.   

Abstract

Dilated cardiomyopathy (DCM) is a common yet challenging cardiac disease. Great strides have been made in improving DCM prognosis due to heart failure but sudden cardiac death (SCD) due to ventricular arrhythmias remains significant and challenging to predict. High-risk patients can be effectively managed with implantable cardioverter defibrillators (ICDs) but because identification of what is high risk is very limited, many patients unnecessarily experience the morbidity associated with an ICD implant and many others are not identified and have preventable mortality. Current guidelines recommend use of left ventricular ejection fraction and New York Heart Association class as the main markers of risk stratification to identify patients who would be at higher risk of SCD. However, when analysing the data from the trials that these recommendations are based on, the number of patients in whom an ICD delivers appropriate therapy is modest. In order to improve the effectiveness of therapy with an ICD, the patients who are most likely to benefit need to be identified. This review article presents the evidence behind current guideline-directed SCD risk markers and then explores new potential imaging, electrophysiological and genetic risk markers for SCD in DCM. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arrhythmias; cardiac; cardiomyopathy; defibrillators; dilated; electrocardiography; implantable

Mesh:

Year:  2022        PMID: 34670824     DOI: 10.1136/heartjnl-2021-319971

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   7.365


  1 in total

1.  Fragmented QRS Pattern in Patients with COVID-19: Further Insights into Its Temporal and Mechanistic Features.

Authors:  Gökay Taylan; Cihan Öztürk; Kenan Yalta
Journal:  Anatol J Cardiol       Date:  2022-03       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.